

P&T Motion History
Calcitonin Gene-Related Peptide Inhibitors (CGRP)

Drugs reviewed	Motion	Date reviewed	Surveillance accepted as adequate	Reiteration of prior motion	Decision
eptinezumab erenumab fremanezumab galcanezumab rimegepant ubrogepant	Provide an updated class review.	December 15, 2021	No Park Chawla		Passed unanimous
	<p>After considering the evidence of safety and efficacy for the treatment of migraine prophylaxis, I move that eptinezumab, erenumab, fremanezumab, galcanezumab are safe and efficacious for the treatment of their approved indications. These CGRP Inhibitors should be second line agents on the Washington PDL. Erenumab, eptinezumab, fremanezumab, and galcanezumab can be subject to therapeutic interchange in the Washington preferred drug list.</p> <p>After considering the evidence of safety and efficacy for the treatment of acute migraine, I move that rimegepant and ubrogepant are safe and efficacious for the treatment of their approved indications as second line agents on the Washington PDL. Rimegepant and ubrogepant can be subject to therapeutic interchange with each other in the Washington preferred drug list.</p> <p>Motion: Park 2nd: Lee</p>	August 19, 2020	NA	No	Passed unanimous

Bold = new this update
 Grey = not FDA approved
 12/16/2021